At the bottom of Innova's PR yesterday, quote-
Post# of 22456
In addition, Innova partners with Ashfield Healthcare to provide consulting and implementation services to governments and corporations.
Who is Ashfield Healthcare?
AH is a division of UDG Healthcare (Based in England)
https://www.udghealthcare.com/our-divisions/ashfield/
UDG Healthcare is a global leader in healthcare advisory, communications, commercial, clinical and packaging services. The Group is organised and managed across two divisions: Ashfield and Sharp, and employs 9,000 people in 29 countries.
Ashfield, part of UDG Healthcare plc, is a global leader in commercialization services for the healthcare industry. https://www.ashfieldhealthcare.com/en/
We partner with our clients across Advisory, Healthcare Communications, Commercial, Patient Solutions and Medical Affairs to build creative, scalable and tailored health solutions that are executed flawlessly, to deliver positive outcomes for patients and add value to your business.
Advisory
Partnering strategically with clients to accelerate performance by applying healthcare industry expertise with outstanding execution.
Healthcare Communications
Connecting insight, intelligence and expertise to flawlessly execute powerful, multichannel communication solutions.
Commercial
Delivering tailored, scalable and effective sales and marketing solutions to maximize our clients’ returns.
Patient Solutions
Providing agile, innovative educational and adherence support services to achieve better outcomes.
Medical Affairs
Applying in-depth knowledge and unsurpassed expertise in all aspects of medical affairs.
In looking over the Ashfield Healthcare website, I see they advise on Covid-19 issues. Ashfield has a few thousand people salesforce in over two dozen countries and Innova can supply the tests and analytics for Ashfield to better advise their clients on Covid. Employers could implement their own Covid test protocols for their employees. This partnership allows Ashland to not only be advisory but to also implement their programs supported by Innova products for testing and analytics.
This is a missing piece in Ashland's offerings, and expands Innova's worldwide exposure. Ashland is an international salesforce for a comprehensive Covid solution for governments and companies. Very few governments have as sophisticated a NHS as England, or companies that are prepared to deal with Covid.
----
Innova's purchase of Biological Laboratory, or BIOLAB, a clinical laboratory focusing on endocrinology, cytology, toxicology and molecular studies gives Innova an R&D division 15 miles from its home office that can create and develop new quantum dot test for other diseases and viruses rapidly, and in the USA. BIOLAB also performs molecular and antibody testing services for the coronavirus, which can be expanded.
“Today’s acquisition of BIOLAB not only expands our R&D; and clinical study management capability in the U.S. but also our ability to supply diagnostic services at large-scale to both corporate and government clients,” Innova Medical Chief Executive Daniel Elliott said in a statement. “With BIOLAB, we increase our robust ability to provide diagnostic tests and to manufacture in-house diagnostic services.”
----
Innova Medical Group, Inc. (IMG), the world's largest manufacturer of rapid antigen test kits for SARS-CoV-2, acquires MPS Medical Inc. (est. 2014), a Calif.-based, FDA registered, medical device manufacturer with an initial production capacity of more than 700,000 SARS-CoV-2 antigen rapid test kits per shift, immediately increasing IMG's global production capacity of the rapid antigen test kits to nearly 9 million units a day. Under the new, IMG ownership, MPS Medical plans to aggressively ramp up its capacity to multi-millions of units per day in Calif., anticipating robust demand for IMG's SARS-CoV-2 rapid qualitative test kits in the USA, and globally.
----
In less than a month, Innova has purchased a Certified Clinical Lab which meets government standards for certain testing abilities not needing FDA approval, and an inhouse nearby R&D center for new quantum dot tests, a manufacturing facility that can produce at least 25% of Innova's production now and can be expanded, and an international sales force aligned with its long-range goals. Thats Blitzscaling, folks!